Zobrazeno 1 - 10
of 216
pro vyhledávání: '"Richard A Hubner"'
Autor:
Angela Lamarca, Richard A Hubner, Zainul Abedin Kapacee, Juan W Valle, Mairéad G McNamara, Lindsay E Carnie, Kate Vaughan, Lynne McCallum, Alison Backen, Jorge Barriuso, Marc Abraham
Publikováno v:
BMJ Open, Vol 11, Iss 5 (2021)
Introduction Pancreatic exocrine insufficiency (PEI) in patients with pancreatic malignancy is well documented in the literature and is known to negatively impact on overall survival and quality of life. A lack of consensus opinion remains on the opt
Externí odkaz:
https://doaj.org/article/fead87f1e2624ad18d86d70b104b093f
Autor:
Daniel Netto, Melissa Frizziero, Victoria Foy, Mairéad G. McNamara, Alison Backen, Richard A. Hubner
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5206-5223 (2024)
Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer-associated mortality, with a rising global incidence. A paucity of strong predictive risk factors mean screening programmes are difficult to implement. Historically, a lack of i
Externí odkaz:
https://doaj.org/article/82cdbede92d547bc8b5e3d4f02cac346
Autor:
Angela Lamarca, Salvatore Galdy, Jorge Barriuso, Sharzad Moghadam, Elizabeth Beckett, Jane Rogan, Alison Backen, Catherine Billington, Mairéad G McNamara, Richard A Hubner, Angela Cramer, Juan W Valle
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0206007 (2018)
INTRODUCTION:Expression of human epidermal growth factor receptor (HER)2 and HER3 have been investigated in small BTC studies using variable scoring systems. METHODS:HER2 and HER3 overexpression/amplification were explored following internationally a
Externí odkaz:
https://doaj.org/article/63bba2cc6e3d473387d7aa195af23fce
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e25164 (2011)
PurposeDespite discrepant results on clinical utility, several trials are already prospectively randomizing non-small cell lung cancer (NSCLC) patients by ERCC1 status. We aimed to characterize the prognostic and predictive effect of ERCC1 by systema
Externí odkaz:
https://doaj.org/article/6d23c15f72c544d1ba6ec3553e94e073
Autor:
Jianming Xu, Ken Kato, Eric Raymond, Richard A Hubner, Yongqian Shu, Yueyin Pan, Sook Ryun Park, Lu Ping, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, Lin Shen, Takashi Kojima, Evgeny Gotovkin, Ryu Ishihara, Lucjan Wyrwicz, Eric Van Cutsem, Paula Jimenez-Fonseca, Chen-Yuan Lin, Lei Wang, Jingwen Shi, Liyun Li, Harry H Yoon
Publikováno v:
The Lancet Oncology. 24:483-495
Autor:
Reem D Mahmood, Kathryn Graham, Jack Gleeson, Richard A Hubner, Juan W Valle, Mairéad G McNamara
Publikováno v:
Immunotherapy. 15:517-530
There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of
Autor:
Simon Gray, Angela Lamarca, Mairéad G. McNamara, Julien Edeline, Karen Piper‐Hanley, Juan W. Valle, Richard A. Hubner
Publikováno v:
Liver Cancer International. 4:13-27
Autor:
Omar Fakih, Suraiya S. Haddad, Sophie Walker, Julien Edeline, Florien Estrade, Xin Wang, Angela Lamarca, Mairéad G. McNamara, Juan W. Valle, Richard A. Hubner
Publikováno v:
Liver Cancer International. 4:5-12
Autor:
Mairéad G. McNamara, Melissa Frizziero, Timothy Jacobs, Angela Lamarca, Richard A. Hubner, Juan W. Valle, Eitan Amir
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: There is no standard second-line treatment for patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma (EP-PD-NEC). This study explored data evaluating second-line treatment in these patients. Methods: A sear
Externí odkaz:
https://doaj.org/article/ac9dacadd8cb4122b077bd15b826da88
Autor:
McNamara, Simon Gray, Octave Letissier, Constance d’Abrigeon, Dinakshi Shah, Stephen Wardell, Olusola Faluyi, Angela Lamarca, Richard A. Hubner, Julien Edeline, Juan W. Valle, Mairéad G.
Publikováno v:
Cancers; Volume 15; Issue 11; Pages: 3047
Phase 3 trials have established standard first-line (1L) and 2L systemic therapy options for patients with advanced biliary cancer (ABC). However, a standard 3L treatment remains undefined. Clinical practice and outcomes for 3L systemic therapy in pa